CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Diacetyl‐bis(4‐methyl‐3‐thiosemicarbazonato)copper II(Cu II(atsm)) ameliorates neurodegeneration and delays disease progression in mouse models of amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), yet the mechanism of action remains uncertain. Promising results were recently reported for separate Phase 1 studies in ALS patients and PD patients. Affected tissue in these disorders shares features of elevated Fe, low glutathione and increased lipid peroxidation consistent with ferroptosis, a novel form of regulated cell death. We therefore evaluated the ability of Cu II(atsm) to inhibit ferroptosis. Experimental Approach: Ferroptosis was induced in neuronal cell models by inhibition of glutathione peroxidase‐4 activity with RSL3 or by blocking cystine uptake with erastin. Cell viability and lipid peroxidation were assessed and the efficacy of Cu II(atsm) was compared to the known antiferroptotic compound liproxstatin‐1. Key Results: Cu II(atsm) protected against lipid peroxidation and ferroptotic lethality in primary and immortalised neuronal cell models (EC 50: ≈130 nM, within an order of magnitude of liproxstatin‐1). Ni II(atsm) also prevented ferroptosis with similar potency, whereas ionic Cu II did not. In cell‐free systems, Cu II(atsm) and Ni II(atsm) inhibited Fe II‐induced lipid peroxidation, consistent with these compounds quenching lipid radicals. Conclusions and Implications: The antiferroptotic activity of Cu II(atsm) could therefore be the disease‐modifying mechanism being tested in ALS and PD trials. With potency in vitro approaching that of liproxstatin‐1, Cu II(atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis‐related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 1×
“Recent work has implicated ferroptosis, a regulated cell death pathway characterised by Fe-dependent lipid peroxidation in ALS, PD, Alzheimer's disease (AD) and stroke (Guiney, Adlard, Bush, Finkelstein, & Ayton, 2017; Masaldan, Bush, Devos, Rolland, & Moreau, 2018; Stockwell et al., 2017).”
BackgroundSelf-citationInactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14153 · Cited by 1,338 · cited 2×
“The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018).”
MethodFerrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411006a · Cited by 1,146 · cited 2×
“Liproxstatin-1 and ferrostatin-1 each contain an aromatic amine that is involved in rapid H-atom transfer to autoxidation chain- carrying lipid peroxy radicals (Figure 1) important for their radical quenching activity (Skouta et al., 2014).”
BackgroundDo Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689 · cited 1×
“Ferrostatin-1 and liproxstatin-1 have been reported to res- cue ischaemia reperfusion injury and stroke models (Friedmann Angeli et al., 2014; Tuo et al., 2017) and PD (Do Van et al., 2016).”
BackgroundAdlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Self-citationRaven, E. P., Lu, P. H., Tishler, T. A., Heydari, P., & Bartzokis, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130209 · Cited by 270
Reed, T. T., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2009) · Brain Research · doi:10.1016/j.brainres.2009.04.009 · Cited by 190
Cited by
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications
Stockwell, B. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.003 · Cited by 3,056
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
“Recently promising results were reported for the use of an anti-ferroptotic compound in phase I clinical trials in amyotrophic lateral sclerosis (ALS) patients and PD patients.(236) Therefore, ferroptosis may play an essential role in the pathogenesis of various neurodegenerative diseases, and anti-ferroptotic strateg…”
BackgroundSelf-citationMolecular mechanisms of cell death in neurological diseases
Moujalled, D., Strasser, A., & Liddell, J. R. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00814-y · Cited by 749
“or erastin in neural cells in vitro and in a cell-free lipid peroxidation system [122].”
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Self-citationThe chemistry and biology of ferroptosis
Stockwell, B. R., & Jiang, X. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.03.013 · Cited by 429
“Cu(II)atsm has also been reported to inhibit ferroptosis, probably through radical-trapping activity (Southon et al., 2020).”
Background
Metadata
- Authors
- Southon, A., Szostak, K., Acevedo, K. M., Dent, K. A., Volitakis, I., Belaidi, A. A., Barnham, K. J., Crouch, P. J., Ayton, S., Donnelly, P. S., & Bush, A. I.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2020-01-14
- Volume
- 177
- Issue
- 3
- Pages
- 656-667
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2981700910
- Cited by
- 136
- References
- 8
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. https://app.cochat.ai/papers/10.1111/bph.14881
- The paper
- Southon, A., Szostak, K., Acevedo, K. M., Dent, K. A., Volitakis, I., Belaidi, A. A., Barnham, K. J., Crouch, P. J., Ayton, S., Donnelly, P. S., & Bush, A. I. (2020). CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. British Journal of Pharmacology. https://doi.org/10.1111/bph.14881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.